Received Regulatory Clearance in Europe to Open First Clinical Trial Site for Phase III PNH Naïve Trial CAPSTONE, the Phase III Naïve PNH Trial Expected to …
Press Release
Akari Therapeutics to Present at the Leerink Partners Global Healthcare Conference
NEW YORK and LONDON, February 7, 2018 - Akari Therapeutics, Plc (NASDAQ:AKTX) (“Akari” or “the Company”), a biopharmaceutical company focused on the development …
Akari Therapeutics Announces Completion of Phase II COBALT Trial of Coversin in Patients with PNH and Further Progress of Clinical Trials
The final three Paroxysmal Nocturnal Hemoglobinuria (PNH) patients enrolled into the Phase II COBALT trial with the revised dosing regimen had median LDH of …
Akari Therapeutics Strengthens Board with Two Senior Industry Appointments
NEW YORK and LONDON, Jan. 23, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc(NASDAQ:AKTX) (“Akari” or “the Company”), a biopharmaceutical company focused on …
[Read more...] about Akari Therapeutics Strengthens Board with Two Senior Industry Appointments
Akari Therapeutics Announces Phase II COBALT trial of Coversin™ in Patients with PNH Met the Primary Endpoint
Last three patients enrolled into the Phase II COBALT trial on the new dosing regimen (45 mg per Day) saw a more rapid decline in LDH than those in the original …
